BioControl heart device implanted at two more locations
The company is testing its CardioFit device to treat congestive heart failure in Europe, Israel, and Australia.
The CardioFit system works by applying electrical impulses to the vagus nerve. A sensing electrode in the right ventricle detects the patient’s heart rate and is used to control nerve stimulation.
The clinical trial study is taking place at sites in Europe, Israel, and Australia. In addition to Bergamo and Mannheim, Policlinico S.Matteo University Hospital in Pavia, Italy; Otto-von-Guericke University Hospital in Magdeburg, Germany; University Hospital Maastricht, in Maastricht, Netherlands, and Clinical Center of Serbia in Belgrade, Serbia are also enrolling patients for the CardioFit system study, and all of them have already successfully implanted the device in trial patients. A total of thirty patients will be enrolled in the study.
BioControl develops and markets implantable devices for the treatment of autonomic disorders, conditions whereby the autonomic nervous system ceases to function properly, resulting in a disruption to the control of involuntary body processes. The devices enable controlled electrical stimulation of various nerves to achieve therapeutic results.
Published by Globes [online], Israel business news - www.globes.co.il - on August 1, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options